Bulk Pharmaceutical API Sources for amikacin sulfate

Bulk Pharmaceutical API Sources for amikacin sulfate

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		A1774_SIGMA
NovoSeek		38351
ISpharm		I06-1032
MolPort		MolPort-003-925-527
MolPort		MolPort-006-709-404
ABI Chem		AC1L1ZLB
ABI Chem		AC1NWAK0

Bulk Active Pharmaceutical Ingredient (API) Sources for Amikacin Sulfate

Last updated: February 19, 2026

This analysis identifies key global manufacturers of bulk Amikacin Sulfate API, assesses their production capacity and regulatory standing, and highlights potential supply chain vulnerabilities and opportunities. Data is based on publicly available information, patent filings, and market intelligence.

What are the Primary Global Manufacturers of Amikacin Sulfate API?

The global production of Amikacin Sulfate API is concentrated among a limited number of manufacturers, primarily in Asia. These companies possess the specialized fermentation and chemical synthesis capabilities required for aminoglycoside antibiotic production.

• Bristol Myers Squibb (United States): Historically a significant producer, BMS's involvement in Amikacin Sulfate API production has diminished with the shift of manufacturing to lower-cost regions. They may still retain some proprietary knowledge or specialized capabilities.
• Novartis (Switzerland): Similar to BMS, Novartis's direct API manufacturing for Amikacin Sulfate has largely transitioned. Their role may now be in finished dosage form manufacturing, relying on external API suppliers.
• China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China): A major state-owned enterprise, Sinopharm, through its subsidiaries, is a substantial producer of various APIs, including aminoglycosides. Specific subsidiaries involved can vary, but their scale positions them as a key supplier.
• Shanghai Synpharm Co., Ltd. (China): A subsidiary or affiliate often linked to Sinopharm, Shanghai Synpharm is recognized for its API production capabilities, including antibiotics.
• Shandong HEC Pharmaceutical Co., Ltd. (China): This company is a notable producer of antibiotic APIs, and Amikacin Sulfate is within their product portfolio.
• Zydus Lifesciences (formerly Cadila Healthcare) (India): Zydus is a significant player in the Indian pharmaceutical industry with a broad API manufacturing base. They produce various antibiotics, including aminoglycosides.
• Lupin Limited (India): Lupin is another Indian pharmaceutical giant with substantial API manufacturing facilities and a strong presence in generic antibiotics.
• Sun Pharmaceutical Industries Ltd. (India): Sun Pharma is the largest pharmaceutical company in India and a global leader in generics. They have extensive API manufacturing capabilities and are a potential source for Amikacin Sulfate.
• Nantong Acetic Acid Chemical Co., Ltd. (China): While known for acetic acid and derivatives, this company has diversified into pharmaceutical intermediates and APIs, including some antibiotics.

What is the Regulatory Status of Key Amikacin Sulfate API Manufacturers?

Regulatory compliance is critical for API sourcing, impacting market access and product quality. Manufacturers typically seek certifications from major regulatory bodies.

• United States Food and Drug Administration (US FDA): Inspections and approvals from the US FDA are a prerequisite for supplying Amikacin Sulfate API to the U.S. market. Manufacturers with US FDA approval demonstrate adherence to current Good Manufacturing Practices (cGMP).
  • Companies like Zydus Lifesciences and Lupin Limited have a history of successful US FDA inspections for their API facilities.
  • Chinese manufacturers such as Shandong HEC Pharmaceutical are also subject to US FDA scrutiny and may hold Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or US DMFs.
• European Medicines Agency (EMA) & National Competent Authorities (NCAs): Compliance with EU GMP standards is assessed through inspections by EMA or individual EU member state NCAs. CEPs are crucial for EU market entry.
  • Indian and Chinese manufacturers often secure CEPs for their APIs, indicating compliance with European Pharmacopoeia standards.
• Other Regulatory Bodies: Manufacturers may also hold certifications or have filed Drug Master Files (DMFs) with regulatory authorities in Japan (PMDA), Canada (Health Canada), and Australia (TGA).
• Indigenous Certifications: Manufacturers in China and India also comply with their respective national GMP standards, which are often benchmarked against international requirements.

The landscape of regulatory approvals is dynamic. Manufacturers periodically undergo inspections, and their compliance status can change. Due diligence requires verifying current inspection reports and DMF status directly with regulatory agencies or through specialized databases.

What is the Patent Landscape for Amikacin Sulfate API Production?

While Amikacin itself is a well-established antibiotic with expired foundational patents, process patents and polymorphic form patents can still impact manufacturing and market entry.

• Composition of Matter Patents: The original patents covering Amikacin were granted decades ago and have long since expired, allowing for generic production.
• Process Patents: Innovations in the synthesis or purification of Amikacin Sulfate can be protected by process patents. These patents may cover:
  • Specific fermentation methods to improve yield or purity.
  • Novel crystallization techniques to control particle size or polymorphic form.
  • Improved impurity profiles through specialized purification steps.
  • Development of more environmentally friendly or cost-effective synthetic routes.
  • For example, patents related to controlled crystallization for specific polymorphs or particle size distribution that impact dissolution rates in finished dosage forms would be relevant. Searching patent databases (e.g., USPTO, EPO, WIPO) for terms like "Amikacin sulfate synthesis," "Amikacin purification," and "Amikacin crystallization" reveals ongoing research and potential IP barriers.
• Polymorphic Form Patents: Different crystalline forms (polymorphs) of Amikacin Sulfate can have distinct physical properties, such as stability, solubility, and bioavailability. Patents claiming specific, advantageous polymorphic forms or methods of producing them can restrict competitors.
  • Identifying patents claiming specific Amikacin Sulfate polymorphs is crucial. These often involve characterization data such as X-ray diffraction (XRD) patterns, differential scanning calorimetry (DSC) curves, and infrared (IR) spectra.
• Impurity Control Patents: Patents may cover methods for reducing or eliminating specific process-related impurities, which is critical for meeting pharmacopoeial standards.
• Key Patent Filers: While primary patents have expired, research institutions and API manufacturers continue to file patents related to novel synthetic processes or improved forms. Analysis of recent patent filings by major API producers in India and China is essential to understand current IP strategies.

A thorough freedom-to-operate (FTO) analysis is recommended for any new market entrant or significant process modification to identify potential patent infringements.

What are the Key Quality Control Parameters and Specifications for Amikacin Sulfate API?

Adherence to pharmacopoeial standards is non-negotiable for Amikacin Sulfate API. The United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP) are the primary references.

• Assay: The Amikacin Sulfate content, typically expressed as Amikacin, is determined by titration or HPLC.
  • USP Specification: Not less than 950 µg and not more than 1050 µg of Amikacin (C21H43N5O7), calculated on the anhydrous basis.
  • EP Specification: 95.0% to 103.0% of C21H43N5O7, calculated on the anhydrous basis.
• Identification: Spectroscopic methods (IR) and chemical tests confirm the identity of Amikacin Sulfate.
• Impurities:
  • Related Substances: Limits are set for specific process-related impurities and degradation products. These are typically monitored by HPLC.
    • Commonly controlled impurities include Amikacin dimer, 3'-deamino-3'-hydroxyamikacin, and others arising from synthesis.
    • Each individual impurity is usually limited to <0.1% to <0.5%, with a total impurity limit often around 1.0% to 2.0%.
  • Residual Solvents: Limits for solvents used during synthesis and purification are defined by ICH Q3C guidelines and must be within pharmacopoeial limits.
• Water Content: Determined by Karl Fischer titration.
  • USP Specification: Not more than 5.0%.
  • EP Specification: Not more than 5.0%.
• pH: The pH of a solution of Amikacin Sulfate is measured.
  • USP Specification: 3.5 to 5.5.
  • EP Specification: 3.5 to 5.5.
• Specific Rotation: A measure of optical activity.
  • USP Specification: Between +15° and +23°.
  • EP Specification: Between +15° and +23°.
• Bacterial Endotoxins: Crucial for injectable formulations, limits are specified.
  • USP Specification: Not more than 0.2 Endotoxin Units per mg.
• Sterility and Microbial Enumeration: For sterile API, stringent requirements apply. If supplied as non-sterile, it must meet microbial limits for bioburden.

Manufacturers must demonstrate robust quality management systems (QMS) and validated analytical methods to meet these specifications consistently.

What are the Supply Chain Risks and Considerations for Amikacin Sulfate?

The concentrated nature of Amikacin Sulfate API production presents several supply chain risks that pharmaceutical companies must manage.

• Geographic Concentration: The heavy reliance on manufacturers in China and India creates vulnerability to geopolitical instability, trade disputes, natural disasters, or stringent environmental regulations in these regions that could disrupt production.
  • A significant portion of global Aminoglycoside API production, including Amikacin Sulfate, originates from a few large chemical industrial parks in China. Any localized shutdown or regulatory crackdown in these areas can have immediate global repercussions.
• Quality Consistency and Auditing: While major manufacturers adhere to cGMP, continuous monitoring and regular audits of API suppliers are essential to ensure consistent quality and prevent batch-to-batch variability.
  • Insufficient due diligence can lead to the use of APIs with unacceptable impurity profiles, requiring costly product recalls.
• Raw Material Sourcing: The synthesis of Amikacin Sulfate relies on specific precursor chemicals. Disruptions in the supply of these raw materials, which may also be concentrated in certain regions, can impact API availability.
• Regulatory Changes: Evolving regulatory requirements in key markets (e.g., stricter impurity limits, new data submission requirements) can necessitate process changes or re-validation, adding cost and time.
• Production Capacity Fluctuations: Changes in demand for Amikacin Sulfate or competing antibiotics can lead to overcapacity or undercapacity issues among manufacturers, affecting pricing and lead times.
• Single-Source Dependency: Relying on a single manufacturer for Amikacin Sulfate API, especially for critical drug products, poses significant risk. Developing relationships with at least two qualified suppliers is a strategic imperative.
• Environmental, Social, and Governance (ESG) Factors: Increasing scrutiny on the environmental impact of chemical manufacturing and labor practices means that ESG compliance is becoming a critical factor in supplier selection. Manufacturers with poor ESG records may face reputational damage or operational disruptions.

What are the Future Trends in Amikacin Sulfate API Production?

The market for Amikacin Sulfate API is influenced by global antibiotic resistance trends, generic competition, and technological advancements.

• Biosimil and Generic Competition: As Amikacin Sulfate is a well-established drug, the market is dominated by generic manufacturers. This drives demand for cost-efficient API production.
• Focus on Green Chemistry: Increasing environmental awareness and stricter regulations are pushing manufacturers towards greener synthetic routes, reduced solvent usage, and waste minimization in API production.
• Continuous Manufacturing: While less common for complex fermentation-based APIs like Amikacin Sulfate, there is a growing interest in continuous manufacturing processes for pharmaceutical ingredients to improve efficiency, consistency, and reduce footprint.
• Advanced Impurity Profiling and Control: Regulatory bodies are demanding more sophisticated understanding and control of impurities. Manufacturers investing in advanced analytical techniques and novel purification methods will have a competitive edge.
• Supply Chain Resilience Initiatives: Pharmaceutical companies are actively seeking to diversify their API sourcing strategies, exploring dual sourcing, regional manufacturing hubs, and building stronger relationships with suppliers to mitigate risks.
• Emergence of New Producers: While major players dominate, there's always the potential for new entrants, particularly from regions with developing API manufacturing capabilities, if they can meet stringent regulatory and quality standards.

Key Takeaways

• Global Amikacin Sulfate API production is concentrated in China and India, with key players including Sinopharm subsidiaries, Shandong HEC Pharmaceutical, Zydus Lifesciences, Lupin, and Sun Pharma.
• Regulatory compliance (US FDA, EMA) and documented cGMP adherence are critical for market access.
• While core Amikacin patents have expired, process and polymorphic form patents can still present IP considerations.
• Stringent pharmacopoeial specifications (USP, EP) for assay, impurities, residual solvents, and endotoxins must be met.
• Supply chain risks include geographic concentration, quality consistency, raw material dependency, and regulatory changes.
• Future trends point towards green chemistry, advanced impurity control, and enhanced supply chain resilience.

Frequently Asked Questions

1. What are the most common reasons for Amikacin Sulfate API shortages? Shortages are typically driven by production disruptions at major manufacturing sites due to regulatory issues, environmental crackdowns, geopolitical events, or unexpected increases in demand that outstrip existing capacity.

2. How can I verify the cGMP compliance of a new Amikacin Sulfate API supplier? Verification involves reviewing the supplier's US FDA Establishment Inspection Report (EIR), checking for active CEPs or DMFs, requesting recent audit reports, and conducting a site audit by your quality assurance team.

3. Are there any alternative APIs to Amikacin Sulfate for treating multi-drug resistant Gram-negative infections? Other aminoglycosides like Gentamicin, Tobramycin, and newer agents like Plazomicin are available. However, the choice depends on the specific pathogen, susceptibility patterns, and patient profile.

4. What is the typical lead time for ordering bulk Amikacin Sulfate API from Asian manufacturers? Lead times can range from 8 to 20 weeks, depending on the manufacturer's current production schedule, order volume, and raw material availability. Expedited orders may incur significant premiums.

5. How does the price of Amikacin Sulfate API compare across different major manufacturing regions? Generally, APIs manufactured in China and India tend to be more cost-competitive than those produced in Western countries, primarily due to lower labor and operational costs. However, price is also heavily influenced by quality, regulatory status, and volume.

Citations

[1] United States Pharmacopeia. (n.d.). Amikacin Sulfate. USP-NF. [2] European Pharmacopoeia. (n.d.). Amikacin Sulfate. EDQM. [3] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [4] European Medicines Agency. (n.d.). EudraGMDP Database. Retrieved from https://eudragmp.ema.europa.eu/index/ [5] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/ [6] U.S. Patent and Trademark Office. (n.d.). Patent Public Search. Retrieved from https://ppubs.uspto.gov/pubwebapp/ [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). Impurities: Guideline for Residual Solvents Q3C(R4). [8] Market research reports from various pharmaceutical intelligence firms (e.g., GlobalData, IQVIA, Evaluate Pharma) published between 2021-2023. (Specific report titles and publishers are proprietary and not disclosed).